Pluripotent state transitions coordinate morphogenesis in mouse and human embryos by Shahbazi, Marta N. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1038/nature24675
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Shahbazi, M. N., Scialdone, A., Skorupska, N., Weberling, A., Recher, G., Zhu, M., ... Zernicka-Goetz, M.
(2017). Pluripotent state transitions coordinate morphogenesis in mouse and human embryos. NATURE, 552,
239-243. [7684]. DOI: 10.1038/nature24675
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 15. Aug. 2018
	 1	
 
Pluripotent state transitions coordinate morphogenesis in mouse and 
human embryos 
 
Marta N. Shahbazi1, Antonio Scialdone2,10, Natalia Skorupska1, Antonia Weberling1, 
Gaelle Recher1,3, Meng Zhu1, Agnieszka Jedrusik1, Liani G. Devito4, Laila Noli4, Iain 
C. Macaulay5, Christa Buecker6, Yakoub Khalaf4, Dusko Ilic4, Thierry Voet7,8, John 
C. Marioni2,7,9, & Magdalena Zernicka-Goetz1*. 
 
 
1 Mammalian Embryo and Stem Cell Group, University of Cambridge, Department of 
Physiology, Development and Neuroscience; Downing Street, Cambridge, CB2 3DY, 
UK. 
2 EMBL-European	 Bioinformatics	 Institute	 (EMBL-EBI),	 Wellcome	 Genome	Campus,	Cambridge	CB10	1SD,	UK.	Present	 address:	 Institute	 of	 Epigenetics	 and	 Stem	 Cells,	 Helmholtz	 Zentrum	München,	München,	Germany.	3	present	address:	Bioimaging	and	Optofluidics	group,	 IOGS,	CNRS	&	University	of	Bordeaux.	Rue	Francois	Mitterrand,	33400	Talence,	France.	4	Faculty	of	Life	Sciences	and	Medicine,	King's	College	London,	Women's	Health	Academic	Centre,	Assisted	Conception	Unit,	Guy’s	Hospital,	Great	Maze	Pond,	London	SE1	9RT,	UK.	5	present	address:		Earlham	Institute,	Norwich	Research	Park,	Norwich,	NR4	7UG	6	present	address:	Max	F.	Perutz	Laboratories,	Vienna	Biocenter	(VBC),	Dr.	Bohr-Gasse	9,	1030	Vienna,	Austria.		
7 Wellcome	Trust	Sanger	Institute,	Wellcome	Genome	Campus,	Cambridge	CB10	1SA,	UK.	8	 Laboratory	 of	 Reproductive	 Genomics,	 Department	 of	 Human	 Genetics,	 KU	Leuven,	Herestraat	49,	3000	Leuven,	Belgium.	9 Cancer	Research	UK	Cambridge	 Institute,	University	of	Cambridge,	Cambridge	CB2	0RE,	UK.	10	Present	address:	 Institute	of	Epigenetics	 and	Stem	Cells,	Helmholtz	Zentrum	München,	München,	Germany.	
 
 
* Corresponding author: mz205@cam.ac.uk 
 
Keywords: Pluripotency; Epiblast; Embryonic Stem cells; Epithelial tissue. 
	 2	
The foundations of mammalian development lie in a cluster of embryonic epiblast stem 
cells that, in response to extracellular matrix signaling (ECM), undergo epithelialization 
creating an apical surface in contact with a cavity1,2, a fundamental event for all 
subsequent development. Concomitantly, epiblast cells transit through distinct 
pluripotent states3,4, prior to lineage commitment at gastrulation. These pluripotent 
states have been characterized at the molecular level5, but their biological significance 
remains unclear. Here, we show that exit from an unrestricted naïve pluripotent state is 
required for epiblast epithelialization and generation of the pro-amniotic cavity in 
mouse embryos. Embryonic stem cells locked in the naïve state are able to initiate 
polarization but fail to undertake lumenogenesis. Mechanistically, exit from naïve 
pluripotency activates an Oct4-governed transcriptional program resulting in 
expression of sialomucins and the vesicle tethering and fusion events of lumenogenesis. 
Similarly, culture of human embryos beyond implantation reveals that exit from naïve 
pluripotency triggers amniotic cavity formation and developmental progression. Our 
results add tissue-level architecture as a new criterion for the characterization of 
different pluripotent states, and unveil the relevance of transitions between these states 
during development of the mammalian embryo.  
 
We wished to determine the relationship between morphogenesis of the epiblast, meaning its 
polarization and lumenogenesis, and the transitions between distinct pluripotency states, both 
of which are initiated upon embryo implantation. When we examined the temporal correlation 
between these post-implantation events, we found that as the naïve pluripotency factor Nanog 
became down-regulated6, the anti-adhesive sialomucin protein Podocalyxin7 (Podxl) first 
became polarized apically and then secreted as the lumen appeared (Fig. 1a). Deep-
sequencing analysis at successive implantation stages revealed the kinetics of pluripotent 
transitions. We found that at E4.5 and E4.75 epiblasts grouped together and expressed naïve 
pluripotency genes at similar levels, whereas gene expression in the epiblast at E5.0 was quite 
distinct, with the naive pluripotency genes already downregulated (although Nanog 
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transcription was becoming already low at E4.5-E4.75; Fig. 1b, c, Extended Data Fig. 1a-g, 
Supplementary Table 1).  When considered together with previous datasets8, our findings 
reveal two distinct groups: pre-implantation (E3.5-E4.75) and post-implantation epiblast 
(E5.0-E5.5), in which naïve genes are downregulated to a similar extent at the latter. We also 
noted the upregulation of characteristic post-implantation gene expression at E5.5 compared 
to E5.0 (Extended Data Fig. 1h, i). Therefore, the naïve gene expression network is 
dismantled at lumenogenesis. To determine if there is a causal relationship between these 
events, we cultured E4.5 embryos in IVC19 supplemented with 2i/LIF (MEK inhibitor, GSK3 
inhibitor and Leukemia Inhibitory Factor, LIF), which maintains mouse embryonic stem cells 
(mESCs) in the naïve state10. We found that 2i/LIF preserved expression of Nanog and 
inhibited Podxl expression and lumenogenesis (Fig. 1d-f). We confirmed that the naïve state 
was maintained in ESCs derived from embryos cultured in IVC1 containing 2i/LIF (Extended 
Data Fig. 1j, k). Embryos in IVC1 containing 2i/LIF did not resume development upon 2i/LIF 
removal (Extended Data Fig. 1l-n), indicating that the kinetics of naïve pluripotency exit need 
to be tightly coordinated with morphogenesis.  
 
We next examined the kinetics of polarization and lumenogenesis in relation to naïve 
pluripotency exit using mESCs cultured in matrigel as a model system for embryogenesis1 
(Extended Data Fig. 2a). Upon 2i/LIF removal and after the first cell division, all polarity 
markers we examined exhibited polarized localisation. Upon subsequent divisions, mESCs 
organized into polarized rosettes that opened to form lumens 36 hours after 2i/LIF removal 
(Extended Data Fig. 2b-d). This coincided with the loss of naïve pluripotency gene expression 
(Extended Data Fig. 2e-l; Supplementary Videos 1-3) whereas expression of the core 
pluripotency markers Oct4 and Sox2 was maintained. Expression of early post-implantation 
genes including Otx2 was induced, but primed genes were not expressed (Extended Data Fig. 
2m-q) as in the E5.5 epiblast4,8. When 2i/LIF was removed before cell plating in matrigel, 
lumens formed after 24 hours without a rosette (Extended Data Fig. 3a-c), similar to post-
implantation-like primed human embryonic stem cells (hESCs)11,12.  
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To address whether naïve pluripotency exit is required for polarization, we cultured mESCs in 
matrigel with 2i/LIF (Fig.2a). Surprisingly, cells displayed polarisation of subcellular 
components despite the maintenance of Nanog levels (Fig. 2b-e; Extended Data Fig. 3d-g), 
and the expression of pluripotency genes was indistinguishable from mESCs cultured in 
gelatin (apolar) (Extended Data Fig. 2g-o, 3h-m). Moreover, mESCs recovered from matrigel 
lost their polarized organization, grew as canonical mESCs and contributed to post-
implantation development in chimeras, indicating that their naïve state was intact (Fig. 2f-h; 
Extended Data Fig. 3n-p). As expected13, mESCs cultured without 2i/LIF progressively lost 
the ability to generate colonies (Fig. 2g). In accord with the above results, Dgcr8 KO mESCs, 
which are blocked in the naïve state14, underwent polarization; moreover, preservation of 
naïve pluripotency with a PKC inhibitor15 did not impair polarization (Fig. 2i, j; Extended 
Data Fig. 3q-v). Therefore, mESCs can reversibly initiate polarization without losing their 
naïve character.   
 
By the time mESCs cultured without 2i/LIF formed lumens, mESCs cultured with 2i/LIF 
remained as closed rosettes and expressed the naïve markers Nanog and Rex1, while Oct4 
was expressed at similar levels in both conditions (Fig. 3a-b; Extended Data Fig. 4a-c). 
Electron microscopy revealed that while mESCs formed expanded lumens in the absence of 
2i/LIF, mESCs cultured with 2i/LIF displayed either no, or only rudimentary, lumens despite 
having apically localized tight juntions (TJs) and Golgi (Extended Data Fig. 4d, e). With time, 
rosettes of mESCs in 2i/LIF lost polarization and became disorganized (Fig. 3c-d; Extended 
Data Fig. 4f-h). As we observed in embryos, mESCs cultured in matrigel containing 2i/LIF 
did not resume morphogenesis upon 2i/LIF removal (Extended Data Fig. 4i-l). To test 
whether the lumenogenesis defect was a direct consequence of the pluripotent status, we 
cultured mESCs with combinations of two supplements (2i, MEKi/LIF and GSK3i/LIF) 
sufficient to maintain naïve pluripotency16. All combinations inhibited lumenogenesis and 
preserved Nanog expression (Extended Data Fig. 4m-o). Given a single supplement, mESCs 
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forming lumens showed decreased Nanog expression (Extended Data Fig. 4p, q). Dgcr8 KO 
mESCs expressing high Nanog levels also showed a lumenogenesis defect (Fig. 3e-g; 
Extended Data Fig. 5a-d). Likewise, PKC inhibition preserved Rex1 and Nanog expression, 
and impaired lumenogenesis (Extended Data Fig. 5e-h). Notably, when we first induced naïve 
pluripotency exit and then cultured cells in matrigel containing 2i/LIF, those cells expressing 
Podxl but lacking Nanog formed lumens (Extended Data Fig. 5i-m). Next, we sought to 
identify the transcription factors that regulate lumenogenesis. Constitutive expression of 
Nanog enhances self-renewal17. However, we found that Nanog overexpression in the absence 
of 2i/LIF and serum was insufficient to block lumenogenesis and to preserve the naïve 
network (Extended Data Fig. 5n-r). Similarly, Nanog downregulation was insufficient to 
promote lumenogenesis with 2i/LIF, and Rex1 levels remained constant (Extended Data Fig. 
5s-v). We next focused on Oct4 as, together with Otx2, drives enhancer activation upon naïve 
pluripotency exit18,19. Decreasing Oct4 expression led to defective lumenogenesis and reduced 
Otx2 levels (Fig. 3h-i; Extended Data Fig. 5w, x). These results indicate that the pluripotency 
network directs lumen formation and epithelialization via Oct4.  
 
For further mechanistic insight, we tested whether the fusion of apical vesicles20 mediates 
lumenogenesis. Cells expressing a dominant-negative form of Rab11a (Rab11aS25N)21 failed 
to form lumens (Fig. 4a-b). Apical vesicles carry components involved in lumenogenesis, 
such as Podxl22. Since Podxl was not expressed in naïve conditions (Fig. 1a; Extended Data 
Fig. 6a-d), we evaluated its role in lumenogenesis by RNAi. mESCs lacking Podxl showed a 
lumen formation defect at 48 hours, without alterations in naïve pluripotency exit or 
polarization (Extended Data Fig. 6e-k). To determine the long-term consequences of Podxl 
deficiency, we generated Podxl KO mESCs. Podxl KO mESCs showed defective 
lumenogenesis after 48 hours, but formed lumens by 72 hours (Fig. 4c-d; Extended Data Fig. 
6l-m), in agreement with the lack of lethality in Podxl KO embryos23. This lumenogenesis 
delay was rescued by overexpressing Cd34, a sialomucin expressed at very low levels at 
E5.58 (Extended Data Fig. 6n, p). Moreover, treatment with protamine sulfate, which 
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neutralises the negative charges of sialomucins24, blocked lumen formation at 72 hours (Fig. 
4e-f), indicating that sialomucins mediate lumenogenesis via cell repulsion. Next, we 
analyzed whether Podxl expression was regulated by Oct4-Otx2. We found that Otx2 KO 
mESCs expressed low levels of Podxl and displayed a lumenogenesis delay (Extended Data 
Fig. 7a-d), which was rescued by Otx2 overexpression using a doxycycline (DOX) inducible 
system (Extended Data Fig. 7e-f). In agreement with previous results6,18, Otx2 overexpression 
in the presence of 2i/LIF was able to induce naïve pluripotency exit in 50% of WT and 35% 
of Otx2 KO mESCs. These cells formed lumens despite the presence of 2i/LIF (Extended 
Data Fig. 7g- j). Although Otx2 KO mESCs showed a delay in naïve pluripotency exit, the 
lumenogenesis defect was rescued by over-expression of GFP-Podxl (Extended Data Fig. 7k-
m). Analysis of Oct4 and Otx2 Chip-seq data18 revealed the presence of an intronic enhancer 
approximately 3.5Kbs downstream of the Podxl transcription start site. In naïve conditions 
this enhancer was bound by Oct4 and devoid of the activating H3K27ac mark. Naïve 
pluripotency exit led to Otx2 binding and increased H3K27ac (Extended Data Fig. 7n). 
However, Podxl overexpression was insufficient to rescue lumen formation in naïve cells; 
instead the exogenous Podxl co-localized with Rab11 (Fig. 4g; Extended Data Fig. 7o, p). 
Analysis of the expression of genes involved in the fusion of Podxl-containing vesicles25 in 
E4.5-E5.5 epiblasts8 revealed that the TJ protein Cingulin (Cgn) was induced upon naïve 
pluripotency exit. We confirmed this in embryos and mESCs (Fig. 4h; Extended Data Fig. 8a-
b). In MDCK cells Cgn mediates lumenogenesis by tethering Rab11 vesicles through 
association with the Rab11 interacting protein Fip526. Indeed, we found that Fip5 showed 
polarized localisation and associated with Podxl upon 2i/LIF removal (Extended Data Fig. 
8c). Depletion of Cgn led to a lumenogenesis defect and accumulation of Podxl in the 
cytoplasm (Fig. 4i-j), without affecting naïve pluripotency exit (Extended Data Fig. 8d-e). 
Thus, in mESCs Cgn mediates the apical fusion of Podxl-containing Rab11 vesicles.  
 
The human epiblast also transforms into an epithelium enclosing a lumen (amniotic cavity) at 
implantation2. However, whether this occurs concomitant with a pluripotency change remains 
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unknown. We found that at E6-7, epiblast cells (GATA6-) expressed the naïve factor 
KLF1727 and  lacked PODXL, whereas 4 out of 9 human embryos cultured until E9-1011,28, 
had a PODXL-coated lumen (Fig. 5a-b). Upon addition of inhibitors and growth factors 
(5i/LAF) that preserve naïve pluripotency in hESCs29, embryos failed to form a lumen, 
displayed high levels of KLF17, NANOG and the naïve marker CD13030, and showed a mild 
increase in apoptosis (Fig. 5b-e; Extended Data Fig. 9a-f).  
 
Finally, we determined the tissue-level characteristics of distinctive human pluripotent states 
in different naïve cultures. hESCs overexpressing NANOG and KLF2 with 2i/LIF are in a 
naïve-like state29,31. We found that presence of DOX upregulated naïve markers and abolished 
lumenogenesis, whereas DOX removal or switching to primed conditions induced naïve 
pluripotency exit and lumenogenesis (Extended Data Fig. 10a-e). In transgene-independent 
naïve conditions (RSet and 5i/LAF29) we found that although NANOG and KLF2 were 
downregulated, naïve markers were highly expressed and lumenogenesis was abolished 
without alterations in the initial polarization (Fig. 5f, g; Extended Data Fig. 10f-m). Switching 
to primed conditions led to both rosette and lumen formation (Extended Data Fig. 10n, o). 
Therefore, in human embryos and hESCs a pluripotent transition is required for amniotic 
cavity formation. 
Our data thus indicates an evolutionary conserved mechanism that unifies transcriptional and 
architectural changes of the epiblast. Failure to exit from naïve pluripotency leads to impaired 
cavity formation and this in turn could contribute to high rates of embryo loss at implantation.  
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Figure legends 
Figure 1: Epiblast gene expression at peri-implantation. a, Immunostaining of mouse 
embryos. Dotted lines indicate the epiblast; arrowheads polarized Podxl; asterisks Podxl in 
primitive endoderm; white long arrows positions used to plot intensity profiles (below). b, 
Principal Component Analysis (PCA) of the gene expression levels of all samples. Numbers 
indicate percentage of variance. c, Heatmap showing expression of core (black), naïve (green) 
and post-implantation (purple) genes. Asterisk/hash symbols indicate genes significantly 
highly/lowly expressed in E4.5-E4.75 compared to E5.0. d, Lumen formation in embryos 
from panel f (n=19 (IVC1) and 15 (IVC1+2i/LIF) embryos) Chi-square test, ***p=0.0007. e, 
Nanog intensity in embryos from panel f (n=19 (IVC1) and 15 (IVC1+2i/LIF) embryos). 
Unpaired Student’s t test, ***p<0.0001. f, Immunostaining of in vitro cultured mouse 
embryos. Dotted lines indicate the epiblast. Arrows indicate lumens.  All scale bars 20 µm. 
 
Figure 2: Naïve mESCs initiate polarization in matrigel. a, Experimental set-up. A: 
analysis. b, Immunostaining of mESCs cultured as indicated in a. Scale bars, 5 µm. c, 
Centrosome positions in cells from panel b (n=60 (+2i/LIF) and 62 (-2i/LIF) centrosomes). 
Unpaired Student’s t test, ns: non-significant. d, Nanog intensity in cells from panel b (n=30 
(+2i/LIF) and 31 (-2i/LIF) spheroids). Unpaired Student’s t test, ***p<0.0001. e, 
Immunostaining of mESCs cultured as indicated in a. Squares denote magnified regions. 
	 11	
Scale bars, 10 µm. f, Experimental set-up. g, Immunostaining of mESCs cultured as indicated 
in f. Scale bars, 50 µm. h, mESC-embryo chimeras generated using H2B-GFP mESCs 
cultured as indicated in f. Scale bars, 40 µm. i, Immunostaining of mESCs. Scale bars, 5 µm. 
j, Centrosome positions in cells from panel i (n=52 (+Gö6983) and 56 (-Gö6983) 
centrosomes). Mann Whitney U test, ns: non-significant. All panels: arrows denote 
polarization; gelatin (G), matrigel (M). 
 
Figure 3: Naïve pluripotency exit is required for lumenogenesis. a, Experimental set-up. 
A: analysis. b-c, Immunostaining of mESCs cultured as indicated in a. Squares denote 
magnified regions and arrows non-polarized cells.  d, Lumen formation in cells from panels 
b-c. (n=40 (+2i/LIF 48h), 40 (-2i/LIF 48h), 21 (+2i/LIF 72h) and 22 (-2i/LIF 72h) spheroids). 
Chi-square test, ***p<0.0001. e, Immunostaining of control and Dgcr8 KO mESCs. Arrows 
indicate lumens. f, Lumen formation in cells from panel e (n=29 (control +2i/LIF), 31 
(control -2i/LIF), 31 (Dgcr8 KO +2i/LIF) and 31 (Dgcr8 KO -2i/LIF) spheroids). Chi-square 
test, ns: non-significant. g, Nanog intensity in cells from panel e (n=20 (control +2i/LIF), 20 
(control -2i/LIF), 19 (Dgcr8 KO +2i/LIF) and 21 (Dgcr8 KO -2i/LIF)). Kruskal-Wallis test, 
*** p<0.0001, *p<0.05. h, Immunostaining of control and Oct4 knock-down mESCs. Arrows 
indicate lumens. i, Lumen formation in cells from panel h (n=39 (control), 53 (Oct4 siRNA 
w/ Oct4) and 32 (Oct4 siRNA w/o Oct4) spheroids). Chi-square test, ***p<0.0001. All 
panels: scale bars, 10 µm; matrigel (M). 
 
Figure 4: Vesicle fusion downstream of naïve pluripotency exit. a, Immunostaining of 
GFP-Rab11a and GFP-Rab11aS25N overexpressing mESCs. Arrows indicate lumens. Scale 
bars, 10 µm. b, Lumen formation in cells from panel a (n=35 (Rab11a WT 48h), 60 (Rab11a 
WT 72h), 39 (Rab11aS25N 48h) and 29 (Rab11aS25N 72h) spheroids). Chi-square test, 
***p<0.0001. c, Immunostaining of heterozygous (HET) and Podxl KO mESCs. Arrows 
indicate lumens. Scale bars, 10 µm. d, Lumen formation in cells from panel c (n=34 (HET), 
32 (clone 1), 30 (clone 2) and 21 (clone 3) spheroids). Chi-square test, *p=0.0245, 
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**p=0.0019, ***p<0.0001. e, Immunostaining of control and protamine sulfate-treated 
mESCs. Arrows point to lumens. Scale bars, 10 µm. f, Lumen formation in cells from panel e 
(n=41 (control) and 40 (protamine sulfate)). Chi-square test, ***p<0.0001. g, Immunostaining 
of GFP-Podxl overexpressing mESCs. Squares denote magnified regions. Scale bars, 10 µm. 
h, Immunostaining of mouse embryos. Dotted lines indicate the epiblast, arrows polarized 
Cgn. Scale bars, 20 µm. i, Immunostaining of control and Cgn knock-down mESCs. Arrows 
point to lumens. Scale bars, 10 µm. j, Lumen formation in cells from panel i (n=40 (control) 
and 39 (Cgn siRNA) spheroids). Chi-square test, ***p<0.0001. All panels: matrigel (M). 
 
Figure 5: Naïve pluripotency exit direct lumenogenesis in human embryos and hESCs.  
a, Immunostaining of day 6-7 human embryos. Squares denote magnified regions, yellow 
arrowheads epiblast and white arrowheads primitive endoderm. Scale bars, 30 µm.  b, 
Immunostaining of day 9-10 human embryos. Dotted lines indicate the epiblast; arrowheads 
the amniotic cavity; white long arrows the position used to plot intensity profiles. Scale bars, 
50 µm and 10 µm (magnified areas). c, Lumen formation in embryos from panels b. Chi-
square test, *p=0.0134. d, PODXL intensity profiles in embryos from panel b. e, KLF17 
intensity in embryos from panel b (n=4 (control w/ lumen), 5 (control w/o lumen) and 11 
(IVC1+5i/LAF) embryos). Unpaired Student’s t test, *p=0.0366. f, Immunostaining of 
hESCs. Arrows indicate lumens. Scale bars, 10 µm.  g, Lumen formation in cells from panel f 
(n=31 (2iL/DOX), 30 (5i/LAF), 30 (RSet) and 30 (mTESR) spheroids). Chi-square test, 
***p<0.0001. h, Model summarizing the findings of the study. 
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Methods 
Human embryos: all human embryo experiments were done in accordance with Human Fertilization 
and Embryology Authority (HFEA) regulations (license reference R0075). Informed consent was 
obtained from all participants, who were informed about the conditions and regulations that apply 
within the HFEA code of practice. The project has also a local approval by a Research Ethics 
Committee (UK National Health Service Research Ethics Committee reference 06/Q0702/90). All 
experimental work conformed to the principles of the WMA Declaration of Helsinki.  All experimental 
work was performed under the HFEA Codes of Practice and the HFEA Act 1990 practices.  
 
Slow-frozen human embryos (day 5-6) were thawed using Quinn’s Advantage Thaw Kit (ART-8016, 
LifeGlobal Group), and vitrified human embryos (day 5-6) were thawed using Kitazato Thawing 
Solutions (VT802-0, Hunter Scientific) following the manufacturer’s instructions. Embryos were 
cultured in Human embryo culture media SAGE 1-Step (67010060A, LifeGlobal Group) for 24 hours 
before Zona pellucida removal with Acidic Tyrode’s solution (T1788, Sigma). Embryos were washed 
in SAGE 1-Step medium and subsequently cultured in a pre- to post-implantation culture method11, as 
previously described. Briefly, embryos were plated in IbiTreat µ-plates (IB-80826, Ibidi GmbH) in 
IVC1 (control) or IVC1 supplemented with 5i/LAF and cultured at 37°C in 21% O2, 5% CO2. 24 hours 
after plating half of the medium was replaced with fresh IVC1. 48 hours after plating half of the 
medium was replaced with fresh IVC2. 72 hours after plating embryos were fixed with 4% PFA 
(15710, Electron Microscopy Sciences). The exact composition of the medium was as follows:  
IVC1 medium: Advanced DMEM/F12 (12634010, ThermoFisher Scientific), 20% v/v heat-inactivated 
FBS (Stem Cell Institute, Cambridge), GlutaMAX (35050061, ThermoFisher Scientific), 25 units/ml 
Penicillin/25 µg/ml Streptomycin (15140122, ThermoFisher Scientific), 1X ITS-X (10 mg/ml insulin, 
5.5 mg/L transferrin, 0.0067 mg/L sodium selenite, 2 mg/L etholamine) (51500056, ThermoFisher 
Scientific), 8 nM β-estradiol (E8875, Sigma), 200 ng/ml Progesterone (P0130, Sigma), and 25 µM N-
aceyl-L-cysteine (A7250, Sigma).  
IVC2 medium: 20% FBS is substituted for 30% KnockOut Serum Replacement (10828010, 
ThermoFisher Scientific). 
5i/LAF: IVC1 and IVC2 were supplemented with 20 ng/mL recombinant human LIF (300-05, 
PeproTech), 20 ng/mL Activin-A (Stem Cell Institute, Cambridge), 8 ng/mL bFGF2 (Stem Cell 
Institute, Cambridge), 1 µM MEK inhibitor PD0325901 (Stem Cell Institute, Cambridge), 0.5 µM 
GSK3 inhibitor IM-12 (BML-WN102-0005, Enzo Life Sciences), 0.5 µM RAF inhibitor SB-590885 
(S0459, LKT Labs), 1 µM Src inhibitor WH-4-023 (5413, Tocris) and 10 µM ROCK inhibitor Y-
27632.   
 
Embryos that attached to the plates and preserved the epiblast lineage were considered for statistical 
analyses. From a total of 87 embryos thawed, 8 were fixed at the blastocyst stage (Fig. 5a). Out of 
these 8 embryos, 4 had epiblast cells as determined by immunofluorescence. The remaining 79 human 
embryos were cultured in the IVC system. Out of these 79 embryos, 34 survived the thawing 
procedure, attached to the plates and survived in the in vitro culture system. Out of these 34, the 
epiblast lineage was preserved in 21 embryos (Fig. 5 and Extended Data Fig. 9).  
 
Mouse embryos: Mice were kept in the Animal House in accordance with national and international 
guidelines. All experiments have been regulated by the Animals (Scientific Procedures) Act 1986 
Amendment Regulations 2012 following ethical review by the University of Cambridge Animal 
Welfare and Ethical Review Body (AWERB). were approved by the Home Office. Animals were 
inspected daily and those that showed health concerns were culled by cervical dislocation.  
Mouse embryos were recovered at embryonic days E4.5 (9am) and E4.75 (4pm) from naturally mated 
F1 (C57Bl6xCBA) or MF1 females by flushing the uterus with M2 medium. Embryos recovered at 
E5.0 (12pm) and E5.5 were manually dissected from the decidua. Females for natural matings were 
used at 3 ± 1 month of age. 
For mESC-embryo chimera experiments embryos were obtained from F1 females superovulated by 
injection of 7.5 IU of pregnant mares’ serum gonadotropin (PMSG, Intervet), followed by injection of 
7.5 IU of human chorionic gonadotropin (hCG, Intervet) and mating with F1 males. Chimeric embryos 
were transferred to F1 females mated with vasectomized CD1 males. Superovulated females were used 
at 6 ± 1 week of age.  
To culture embryos through the pre- to post-implantation transition, the mural trophectoderm of E4.5 
mouse embryos was removed as previously described9. Embryos were subsequently plated in 8 well µ-
Slides (80826, Ibidi) for 24 hours in IVC1 medium.  
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Epiblast dissection at peri-implantation stages: CAG-GFP expressing mouse embryos32 were 
recovered at E4.5, E4.75 and E5.0. The mural trophectoderm (E4.5 and E4.75 embryos) and the 
extraembryonic ectoderm (E5.0 embryos) were removed with a finely pulled glass pipette. Embryos 
were then treated for 15 min at 4°C with Cell Dissociation Buffer (enzyme-free) (13150016, 
ThermoFisher Scientific) followed by pipetting with a narrow glass pipette. This treatment removed 
most of the primitive endoderm/visceral endoderm and polar trophectoderm cells. If remaining GFP-
negative cells were observed, these were separated with a finely pulled glass pipette.  
 
mESC culture: mESCs were routinely cultured in gelatin-coated plates in N2B27-2i-LIF at 37°C, 5% 
CO2, 21% O2. N2B27 medium comprised a 1/1 mix of DMEM/F12 (21331-020, ThermoFisher 
Scientific) and Neurobasal A (10888-022, ThermoFisher Scientific) supplemented with 1% v/v B-27 
(10889-038, ThermoFisher Scientific), 0.5% v/v N-2 (homemade), 100 µM β-mercaptoethanol (31350-
010, ThermoFisher Scientific), Penicillin-Streptomycin (15140122, ThermoFisher Scientific) and 
GlutaMAX (35050061, ThermoFisher Scientific). N-2 supplement contained DMEM/F12 medium 
(21331-020, ThermoFisher Scientific), 2.5 mg/mL Insulin (I9287, Sigma), 10 mg/mL Apo-transferrin 
(T1147, Sigma), 0.75% Bovine Albumin Fraction V (15260037, ThermoFisher Scientific), 20 µg/mL 
Progesterone (p8783, Sigma), 1.6 mg/mL Putrescine dihydrochloride (P5780, Sigma) and 6 µg/mL 
Sodium selenite (S5261, Sigma). 2i-LIF (1 µM MEK inhibitor PD0325901 (Stem Cell Institute, 
Cambridge), 3 µM GSK3 inhibitor CHIR99021 (Stem Cell Institute, Cambridge), and 10 ng/mL LIF 
(Stem Cell Institute, Cambridge)) was added to N2B27 medium to preserve naïve pluripotency. Exit 
from naïve pluripotency was triggered by removal of 2i-LIF. Where indicated, mESCs were cultured 
for a minimum of 4 passages using different combinations of inhibitors (MEKi-LIF, GSK3i-LIF, 
MEKi-GSK3i (2i)). Cells were routinely tested for mycoplasma contamination by PCR.  
 
As an alternative way to preserve naïve pluripotency, mESCs were cultured on Mitomycin C (M4287, 
Sigma) - treated Mouse Embryonic Fibroblasts (MEFs) in Fc medium supplemented with 5 µM 
Gö6983 (G1918, Sigma). Fc medium contained DMEM (41966, ThermoFisher Scientific), 15% Fetal 
Bovine Serum (Stem Cell Institute, Cambridge), Penicillin-Streptomycin (15140122, ThermoFisher 
Scientific), GlutaMAX (35050061, ThermoFisher Scientific), MEM Non-Essential Amino Acids 
(11140035, ThermoFisher Scientific), Sodium Pyruvate (11360070, ThermoFisher Scientific) and 100 
µM β-mercaptoethanol (31350-010, ThermoFisher Scientific).  
 
Cells were routinely passaged with Trypsin EDTA (25300054, ThermoFisher Scientific). Fc medium 
was subsequently added to neutralize the trypsin and cells were centrifuged at 1000 rpm for 5 minutes.  
The following mESC lines were used: E14 WT mESCs (kindly provided by Prof. Austin Smith, Stem 
Cell Institute, Cambridge, UK), 129 WT mESCs (kindly provided by Dr. Jacob Hanna, Weizmann 
Institute of Science, Israel), ΔPE-Oct3/4-GFP mESCs33 (kindly provided by Prof. Azim Surani, The 
Gurdon Institute, Cambridge, UK), Rex1::GFPd2 mESCs34 (kindly provided by Prof. Austin Smith, 
Stem Cell Institute, Cambridge, UK), Nanog-YFP mESCs35, Dgcr8 KO mESCs14 (kindly provided by 
Dr. Jacob Hanna, Weizmann Institute of Science, Israel), Otx2 KO mESCs18 and KH2 dox-inducible 
Nanog mESCs (kindly provided by Dr. Konrad Hochedlinger, Harvard Stem Cell Institute, Boston, 
US).  
 
mESC-embryo chimeras: Chimeras were generated by aggregation of H2B-GFP expressing mESCs 
with 8-cell stage mouse embryos. Briefly, 4-cell stage embryos were recovered by flushing the 
oviducts with M2 medium. Embryos were cultured in KSOM medium (MR-020P-5F, Millipore) until 
the 8-cell stage, at which point zona pellucida was removed by brief treatment with Acidic Tyrode’s 
solution (T1788, Sigma). H2B-GFP expressing mESCs were cultured in 3D matrigel for 24 or 72 
hours. To obtain a single cell suspension, the 3D cultures were treated with Cell Recovery Solution 
(354253, Corning) for 15 min at 4°C. The matrigel was broken into small pieces with a scrapper, the 
resulting suspension was centrifuged and the cell pellet was gently resuspended in Trypsin EDTA 
(25300054, ThermoFisher Scientific). After trypsin inactivation, cells were plated in gelatin-coated 
plates. The resulting ESC colonies were gently dissociated into small clumps and aggregated with the 
8-cell embryos in M2 medium. The resulting chimeras were cultured in KSOM medium until E3.5, 
when they were transferred into pseudo-pregnant females. Chimeras were recovered at E6.5. 
 
mESC derivation: For Nanog-YFP mESC derivation, 8-cell stage mouse embryos were recovered 
from the oviducts of pregnant females and cultured in KSOM (MR-020P-5F, Millipore) in the presence 
of 2i. 24 h later, the medium was changed to N2B27-2i-LIF for 48 h. Hatched blastocysts were 
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subsequently plated on Mitomycin C - treated MEFs in Fc medium containing 2i-LIF. 2 days later, 
blastocysts outgrowths were trypsinized and plated to obtain mESC colonies. Positive colonies were 
identified by immunofluorescence and PCR using two different sets of primers: 
Nanog-YFP PCR1 FW1: AGCCTTGGAATGCTGCTCCGC 
Nanog-YFP PCR1 RV1: CAATTAGAGCTATGCAGAGAA 
Nanog-YFP PCR1 RV2: CCACCCCGGTGAACAGCTCC 
Nanog-YFP PCR2 FW1: AGCCTTGGAATGCTGCTCCGC 
Nanog-YFP PCR2 RV1: CTGGTCTGCAGAGCTAGTTC 
Nanog-YFP PCR2 RV2: CCACCCCGGTGAACAGCTCC 
For derivation of mESCs from implantation cultures, 24 hours after culture in IVC1 or IVC1 +2iLIF 
embryos were plated on Mitomycin C – treated MEFs in Fc medium containing 2i-LIF. 2 days later the 
outgrowths were trypsinized and re-plated, and the appearance of dome-shaped mESC colonies was 
monitored.  
 
hESC culture: All hESC experiments were approved by the UK Stem Cell Bank Steering Committee 
and comply with the regulations of the UK Code of Practice for the Use of Human Stem Cell Lines. 
The WIBR3 ΔPE-OCT4-GFP dox-inducible NANOG KLF2 hESC line29 (kindly provided by Prof. 
Rudolf Jaenisch, MIT, Boston US) was routinely cultured in irradiated CF-1 MEFs (GSC-6101G, 
Amsbio) in N2B27-2i-hLIF-dox at 37°C, 5% CO2, 21% O2. N2B27 medium comprised a 1/1 mix of 
DMEM/F12 (21331-020, ThermoFisher Scientific) and Neurobasal A (10888-022, ThermoFisher 
Scientific) supplemented with 2% v/v B-27 (10889-038, ThermoFisher Scientific), 1% v/v N-2 
(17502048, ThermoFisher Scientific), 100 µM β-mercaptoethanol (31350-010, ThermoFisher 
Scientific), Penicillin-Streptomycin (15140122, ThermoFisher Scientific), GlutaMAX (35050061, 
ThermoFisher Scientific), MEM Non-Essential Amino Acids (11140035, ThermoFisher Scientific), 50 
µg/mL BSA (A3311, Sigma) and 0.5% v/v KnockOut Serum Replacement (10828010, ThermoFisher 
Scientific). To preserve naïve pluripotency 2i-hLIF-dox was added to the medium (1 µM MEK 
inhibitor PD0325901 (Stem Cell Institute, Cambridge), 3 µM GSK3 inhibitor CHIR99021 (Stem Cell 
Institute, Cambridge), 20 ng/mL recombinant human LIF (300-05, PeproTech) and 1 µg/mL 
doxycycline hyclate (D9891, Sigma). Cells were routinely passaged once/twice per week by treatment 
with StemPro Accutase reagent (A1110501, ThermoFisher Scientific) for 3 min, followed by addition 
of Fc medium and centrifugation for 3 min at 1000 rpm. Cells were routinely tested for mycoplasma 
contamination by PCR. 
 
To convert naïve hESCs to primed conditions, two days after plating the medium was changed to 
DMEM/F12 (21331-020, ThermoFisher Scientific) supplemented with 15% FBS (10082139, 
ThermoFisher Scientific), 5% KnockOut Serum Replacement (10828010, ThermoFisher Scientific), 
GlutaMAX (35050061, ThermoFisher Scientific), MEM Non-Essential Amino Acids (11140035, 
ThermoFisher Scientific), Penicillin-Streptomycin (15140122, ThermoFisher Scientific), 100 µM β-
mercaptoethanol (31350-010, ThermoFisher Scientific) and 4 ng/mL bFGF2 (Stem Cell Insitute, 
Cambridge). 4 to 5 days later, and when clear primed colonies were identified, cells were passaged 
using Collagenase/dispase (000000010269638001, Sigma) for 15 min, followed by addition of Fc 
medium, centrifugation for 3 min at 1000 rpm and plating in the presence of 10 µM ROCK inhibitor Y-
27632 (72304, Stemcell Technologies) for 24 h. Primed hESCs were switched to a MEF-independent 
culture by using geltrex (A1569601, ThermoFisher Scientific) - coated plates and mTESR1 medium 
(05850, Stemcell Technologies). Primed hESCs cultured in mTESR1 were routinely passaged using 
StemPro Accutase reagent (A1110501, ThermoFisher Scientific). During the first 24 h after passaging 
10 µM ROCK inhibitor Y-27632 (72304, Stemcell Technologies) was added to the medium. 
 
Naïve WIBR3 ΔPE-OCT4-GFP dox-inducible NANOG KLF2 hESCs were plated on CF-1 MEFs and 
two days after plating the medium was switched to transgene independent naïve hESC media. Two 
different formulations were used: 
- 5i/LAF29: N2B27 medium was supplemented with 20 ng/mL recombinant human LIF (300-05, 
PeproTech), 20 ng/mL Activin-A (Stem Cell Institute, Cambridge), 8 ng/mL bFGF2 (Stem Cell 
Institute, Cambridge), 1 µM MEK inhibitor PD0325901 (Stem Cell Institute, Cambridge), 0.5 µM 
GSK3 inhibitor IM-12 (BML-WN102-0005, Enzo Life Sciences), 0.5 µM RAF inhibitor SB-590885 
(S0459, LKT Labs), 1 µM Src inhibitor WH-4-023 (5413, Tocris) and 10 µM ROCK inhibitor Y-
27632.   
- RSet medium (05970, Stemcell Technologies).  
Transgene-independent hESCs were routinely cultured on CF-1 MEFs (GSC-6101G, Amsbio) and 
passaged using StemPro Accutase reagent (A1110501, ThermoFisher Scientific). 
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mESC spheroid formation: to induce polarization and lumenogenesis of mESCs we used matrigel, as 
it can mimic in vitro the basement membrane that surrounds the epiblast at implantation in vivo1. Two 
different protocols were used36: 
- Embedded: pellets containing 20000 mESCs were resuspended in 20 µL of ice-cold Growth Factor 
Reduced Matrigel (356230, BD Biosciences). The solution was placed as a drop in a well of a µ-Slide 8 
well ibiTreat (IB-80826, Ibidi) and incubated for 2 min at 37°C to allow the matrigel to solidify. Next, 
300 µL of medium (N2B27 or Fc depending on the experiment) were added to the well.  
- 3D on top: a well of a µ-Slide 8 well ibiTreat (IB-80826, Ibidi) was covered with 35 µL of ice cold 
Growth Factor Reduced Matrigel (356230, BD Biosciences) and incubated for 2 min at 37°C to allow 
the matrigel to solidify. In the meantime, 20000 mESCs were resuspended in N2B27 and the cell 
suspension was carefully plated on the matrigel-coated well. When approximately 80% of the cells had 
attached to the matrigel (5-10 min after plating) the medium was removed and replaced with N2B27 
containing 5% matrigel. Where indicated mESCs were treated with 50 µg/mL of protamine sulfate 
(1101230005, Merck Millipore) 
 
hESC spheroid formation: hESCs were induced to polarize and form lumens using the 3D on top 
protocol as previously described11. Briefly, a single cell suspension of hESCs was plated on matrigel-
coated µ-Slide 8 well ibiTreat (IB-80826, Ibidi) as detailed above. Upon attachment to the matrigel-
coated surface, the medium was replaced with hESC medium (mTESR or naïve hESC medium 
depending on the experiment) containing 5% matrigel. To avoid single cell-induced primed hESC 
death 10 µM ROCK inhibitor Y-27632 (72304, Stemcell Technologies) was added to the medium for 
24 h. To monitor de dynamics of naïve pluripotency exit and morphogenesis, naïve hESCs were plated 
in 3D matrigel in mTESR medium.  
 
siRNA treatments: mESCs were transfected with Lipofectamine RNAiMAX Transfection Reagent 
(13778030, ThermoFisher Scientific) using a reverse transfection protocol. Briefly, 100000 cells were 
plated on gelatin-coated 12 well plates together with the Lipofectamine RNAiMAX-siRNA mix. 0.5 
µL of a 20 µM siRNA solution were used per well. AllStars negative control siRNAs (1027280, 
Qiagen) were used as control.  
For downregulation of Podxl expression an equimolar mix of the following siRNAs (Quiagen) was 
used: 
SI01383123: AAGAAUGUAAAUGUCUAUUUA 
SI01383130: CUGGAAUUUAUUGAGAGAUUA 
SI01383137: CCCAAUUUCCAUCUCCUAUAA 
For downregulation of Cgn expression an equimolar mix of the following stealth siRNAs 
(ThermoFisher Scientific) was used: 
CgnMSS230393: CCCUCAUCCAUUGCAUCACUGCUUA 
CgnMSS230394: GAAGACAGUUCUGCAGUCCACCAAU 
CgnMSS230395: GGCUUGCCUUUAUGAGUCCUAGUAA 
For downregulation of Nanog expression an equimolar mix of the following siRNAs (Qiagen) was 
used: 
SI01323357: AGCCTTGGAATTATTCCTGAA 
SI04460869: TGCCAGTGATTTGGAGGTGAA 
SI04460883: CAGGTTTCAGAAGCAGAAGTA 
For downregulation of Oct4 expression the following stealth siRNA (ThermoFisher Scientific) was 
used:  
Pou5f1MSS237605: ACCUUCUCCAACUUCACGGCAUUGG 
 
Cloning: Cloning procedures were done using Gateway technology (ThermoFisher Scientific). Briefly, 
the fragment of interest was amplified by PCR to introduce attB sites. This was cloned into a 
pDONR221 vector (kind gift of Jose Silva, Stem Cell Institute, Cambridge, UK) using the BP clonase 
II (11789020, ThermoFisher Scientific). The fragment of interest was further subcloned into pHygro or 
pBlasticidin vector harbouring a hygromycin B and blasticidin resistance cassette respectively (kind 
gift of Jose Silva, Stem Cell Institute, Cambridge, UK) for expression in mammalian cells. The 
recombination reaction was carried out using the LR Clonase II (11791100, ThermoFisher Scientific). 
 
- GFP-Rab11aS25N (dominant negative): a Rab11aS25N-pEGFP plasmid was used as a template for 
cloning (kindly provided by Prof. Jon Clarke, King’s College London, UK). The fragment 
corresponding to GFP-Rab11aS25N was amplified by PCR using the following primers: 
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Rab11a FW: 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGTGAGCAAGGGCGAGGAG 
Rab11a RV:  
GGGGACCACTTTGTACAAGAAAGCTGGGTCTTAGATGTTCTGACAGCACTGC 
- GFP-Podxl: a GFP-Podxl-pEGFP plasmid22 was used as a template for cloning (kindly provided by 
Dr. Arnaud Echard, Institut Pasteur, Paris, France). The fragment corresponding to CD8 tag –VSV-g 
tag – EGFP – Rhodopsin – rabbit Podxl was amplified by PCR using the following primers: 
FW: GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGCCTTACCAGTGACCGC 
RV: GGGGACCACTTTGTACAAGAAAGCTGGGTCTTAGAGGTGCGTGTCTTCCTC 
- GFP-Cd34:  Mouse Cd34 was amplified from cDNA using the following primers: 
Cd34 FW: ACCACGGAGACTTCTACACAAGG 
Cd34 RV: TCACAGTTCTGTGTCAGCCAC 
Using the GFP-Podxl-pEGFP plasmid as a template, the N-terminal region corresponding to CD8-
VSV-G-GFP-Rhodopsin was amplified by PCR using the following primers: 
GFP FW: ATGGCCTTACCAGTGACCGC 
GFP RV: GAATTCCGTCGCATTGGAGAA 
The two fragments were joined by overlap PCR and attB sites were added for cloning into the 
pBlastidicin vector.  
- H2B-GFP: An H2B-GFP expressing plasmid was used as template for cloning (kindly provided by 
Dr. Mirna Perez-Moreno, CNIO, Madrid, Spain). The fragment corresponding to H2B-GFP was 
amplified by PCR using the following primers: 
FW: GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGCCAGAGCCAGCGAAGT 
RV: GGGGACCACTTTGTACAAGAAAGCTGGGTCTTACTTGTACAGCTCGTCCATGC 
 
To generate a WT GFP-Rab11a construct we performed site-directed mutagenesis using the GFP-
Rab11aS25N-pEGFP plasmid as a template. A 4-primer PCR strategy was designed to correct the 
mutated site. The following primers were used:  
Rab11a FW (external): 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGTGAGCAAGGGCGAGGAG 
Rab11a RV (external):  
GGGGACCACTTTGTACAAGAAAGCTGGGTCTTAGATGTTCTGACAGCACTGC 
Rab11a-WT-FW (internal):  
CTGGTGTTGGAAAGTCTAATCTCTTGTCTCGATTTACTCGAAATGAGTTTAATCTCGAAAG 
Rab11a-WT-RV (internal):  
GAGACAAGAGATTAGACTTTCCAACACCAGAATCTCCAATAAGGACAACTTTG 
The two fragments obtained were joined by overlap PCR.  
 
CRISPR/Cas9: genome editing was performed using the CRISPR-Cas9 system as previously 
described37. gRNAs were designed using the MIT CRISPR Design Tool (http://crispr.mit.edu:8079/).  
A two-gRNA strategy was designed in order to remove the initiation ATG. The following gRNAs were 
used:  
gRNA1:CGAACTCCGGAGTCGCGATC  
gRNA2: CTGCAAGCGGTCCGACCACG)  
The gRNA templates were assembled and ligated into the PX459 vector. The following primers were 
used: 
gRNA1 FW: CACCGCGAACTCCGGAGTCGCGATC 
gRNA1 RV: AAACGATCGCGACTCCGGAGTTCG C 
gRNA2 FW: CACCGCTGCAAGCGGTCCGACCACG 
gRNA2 RV: AAACCGTGGTCGGACCGCTTGCAG C 
The two gRNA-expressing constructs were co-transfected into E14 mESCs. 24 hours post-transfection 
2 µg/mL of Puromycin were added to the medium for 48 hours to select for transient transfectants. 
Single cells were subsequently plated on 96 well plates with Mitomycin C (M4287, Sigma) - treated 
Mouse Embryonic Fibroblasts (MEFs) in Fc-2i/LIF medium. Efficient gene editing was assayed by 
PCR using the following primers:  
Podxl Delta FW: ACACCTTCGCTCGTCGCTGC 
Podxl Delta RV: GACTAGGAATAAATCCACGATCTGGCC 
which generated a 485bp WT band and a 200bp KO band.  
Three KO clones were selected for further analyses by RT-PCR (data not shown) and 
immunofluorescence. 
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mESC transfection: mESCs were transfected using Lipofectamine 3000 (L3000001, ThermoFisher 
Scientific) following the manufacturer’s instructions. Briefly, the day before transfection 50000 cells 
were plated on 24 well gelatin-coated plates in N2B27-2i-LIF without antibiotics. For transfection 0.5 
µg of a PiggyBac transposon vector (kind gift of Dr. Jose Silva, Stem Cell Institute, Cambridge, UK) 
and 0.5 µg of either GFP-Podxl-pHygro, GFP-Cd34-pBlasticidin, tetO-Otx2-puro18, H2B-GFP-
pHygro, GFP-Rab11a-pHygro or GFP-Rab11aS25N-pHygro were used. Transfected cells were 
selected with 200 µg/mL of Hygromycin B (10687010, ThermoFisher Scientific), 10 µg/mL of 
Blasticidin (R210-01, ThermoFisher Scientific) or 2 µg/mL of Puromycin (ant-pr-1, Invivogen) and the 
resulting colonies were manually picked and expanded.  
 
Immunofluorescence: Cells and embryos were fixed in 4% PBS/paraformaldehyde (PFA) (15710, 
Electron Microscopy Sciences) for 20 min at RT and subsequently washed twice with 0.1% 
Tween/PBS. To stain centrosomes, cells and embryos were fixed in ice-cold methanol for 5 min at 4°C. 
Peremeabilization was done in PBS containing 0.3% Triton X-100 and 0.1 M glycine for 30 min at RT. 
Cells were incubated with primary antibodies (Supplementary Table 2) at 4°C ON, followed by 
incubation with fluorescently-conjugated Alexa Fluor secondary antibodies (ThermoFisher Scientific) 
for 2 h at RT (Supplementary Table 2). Both primary and secondary antibodies were diluted in 1% 
BSA, 0.1% Tween/PBS.  
 
Images were acquired in an inverted SP5 confocal microscope (Leica Microsystems) with a Leica HC 
PL APO 1.4 NA 63X oil objective or in an inverted SP8 confocal microscope (Leica Microsystems) 
with a Leica HC PL APO CS2 1.4 NA 63x oil objective.  
 
Time-lapse microscopy: Time-lapse images of mESCs were acquired in an inverted SP5 confocal 
microscope (Leica Microsystems) with a Leica HC PL FLUOTAR 0.5 NA 20.0X dry objective. Cells 
were imaged in a humidified chamber with 21% O2 and 5% CO2. Images were taken at intervals of 30 
min with a Z step of 4 µm.  
 
Fixation and staining for serial block face imaging: Samples were fixed by immersion with 2% 
formaldehyde (made from PFA) and 2% vacuum distilled glutaraldehyde, containing 2mmol/L CaCl2, 
in 0.05M sodium cacodylate buffer at 4°C and pH 7.4 for 8 hours at 4°C. They were rinsed for 5 x 3 
minutes in cold cacodylate buffer containing 2mM calcium chloride. After buffer washes, they were 
incubated in 1% osmium ferricyanide for 18 hours at 4°C and rinsed 5 times in Distilled-Deionized 
Water (DIW). This was followed by 30 minutes incubation in 1% thiocarbohydrazide at room 
temperature and 5 more rinses in DIW. Samples were then incubated in 1% uranyl acetate in 0.05 
maleate buffer at pH 5.5 and at 4°C for 48 hours. They were again rinsed with DIW at room 
temperature 5 x 3 minutes, and dehydrated through 2 times each of 50%, 70%, 90%, and 100% ethanol, 
dry ethanol, dry acetone and dry acetonitrile. The dehydrated samples were infiltrated with Quetol 651 
epoxy resin over a period of 5 days. The resin was cured for 48 hours at 65°C. Thin sections were 
prepared with a Leica Ultracut S mounted on 200 mesh copper grids and viewed with a Tecnia G2 
operated at 200kV. 
 
Image analysis: All microscopy data were analyzed using Fiji software38 (http://fiji.sc). For 3D 
reconstructions images were cropped and filter in Fiji and the rendering was done using Chimera 
(v.1.8.1) (https://www.cgl.ucsf.edu/chimera/). For all quantifications, laser power and detector gain 
were maintained constant to quantitatively compare different experimental conditions within a single 
experiment 
- Quantification of nuclear fluorescence intensity in ESCs: DAPI images were binarized and a mask 
was created to segment in 2D the nuclei. These were saved as Regions Of Interest (ROIs), which were 
used to delineate nuclei in the channel of interest, and nuclear fluorescence intensity was measured 
within each ROI. For every ESC spheroid a unique averaged fluorescence intensity value was 
generated. Error bars represent the variability (s.e.m.) across different spheroids from different 
independent experiments. To compare fluorescence intensity values across different experiments, raw 
fluorescence intensity values were normalized to the average fluorescence intensity of the 
corresponding 2iLIF experimental condition.  Using this approach, mESCs were considered to be 
negative for Oct4 (in the Oct4 siRNA group) or negative for Nanog (in the Nanog siRNA group) when 
the average fluorescence of the spheroid was below the 25% percentile of the corresponding control 
group. 
- Quantification of Podxl and Cgn: to determine whether a spheroid was negative for Podxl (in the 
Podxl siRNA group) or negative for Cgn (in the Cgn siRNA group) the Podxl or Cgn channels in the 
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control group were used to set a threshold value of intensity. This treshold was applied to the 
experimental group and the images were binarized. mESC spheroids that did not show any signal based 
on the threshold value of intensity were considered to be negative.   
- Quantification of nuclear fluorescence intensity in embryos: a representative Z plane was chosen for 
every embryo and the fluorescence intensity of epiblast pluripotency genes was measured using the 
DAPI channel to segment the nuclei as mentioned above. To account for changes in fluorescence in the 
Z-axis, the fluorescence intensity of the gene of interest in the epiblast was normalized to the 
fluorescence intensity of DAPI in the epiblast. Error bars represent the variability (s.e.m.) across 
different embryos.  
- Quantification of fluorescence intensity in time-lapse experiments: to quantify the dynamics of naïve 
pluripotency gene expression, the brightfield channel was used to create a mask, and applied to the 
channel of interest as mentioned above. For every time step a single fluorescence value corresponding 
to the average population was measured. Error bars represent the variability (s.e.m.) across different 
fields of view. To account for photobleaching during imaging in Extended Data Fig. 2e the raw 
fluorescence intensity values of the -2i/LIF experimental group were normalized to the raw 
fluorescence intensity values of the 2i/LIF control group (Extended Data Fig. 3k-m) throughout the 
time lapse. All experimental conditions shown in Extended Data Fig. 2e and Extended Data Fig. 3k-m 
were imaged simultaneously.  
- Analysis of centrosome positions: to analyze the position of centrosomes the nucleus-nucleus axis and 
the nucleus-centrosome axis were determined. The angle between both vectors was calculated and the 
XY positions were normalized to the internuclear distance.  
- Analysis of lumen and rosette formation: to quantitatively determine whether rosettes and lumens 
form in embryos and ESC spheroids we immunostained components of the Par polarity complex (either 
aPKC or Par6) and/or Podxl, as they are known to localize to the lumen in 3D in vitro cultures20 and 
are used as bona-fide luminal markers in different model systems39,40. Phalloidin staining was used to 
reveal cell shapes. Lumens and rosettes displayed a polarized organization, whereas disorganized 
structures did not show a polarized localization of Par proteins and/or Podxl. In addition, the 
fluorescence intensity profile was plotted from a line drawn through the location of interest (rosettes or 
lumens). One peak of fluorescence intensity corresponds to a rosette (a closed spot of fluorescence) 
whereas two peaks depict a lumen (two walls and a central depression) (Fig. 1a, Fig. 5d and Extended 
Data Fig. 2b are shown as examples).  
In Extended Data Fig. 9a the F-actin channel was separated from the nanog channel by applying a 
subtract function in Fiji.  
 
RNA extraction and RT-PCR: For RNA extraction of mESCs cultured in matrigel (3D on top 
protocol), the matrigel was first removed by treatment with Cell Recovery Solution (354253, Corning) 
for 15 min at 4°C. To facilitate the depolimerization, the matrigel was manually broken into small 
pieces. Cells were subsequently centrifuged and pellets were washed once with PBS.  
 
RNA was extracted using TRIzol Reagent (15596010, ThermoFisher Scientific) following the 
manufacturer’s instructions. 1 µg of RNA was used to perform a reverse transcriptase reaction in the 
presence of random primers (C1181, Promega), dNTPs (N0447S, New England BioLabs), RNAse 
inhibitor (M0314L, New England BioLabs) and M-MuLV reverse transcriptase (M0253L, New 
England BioLabs). RT-PCR reactions were carried out using Power SYBR Green PCR Master Mix 
(4368708, ThermoFisher Scientific) in a Step One Plus Real-Time PCR machiner (Applied 
Biosystems). The following program was used: 10 min 95°C followed by 40 cycles of 15 sec 95°C 
(denaturing) and 1 min 60°C (annealing and extension). The primers used are listed on Supplementary 
Table 3. 
Mouse gene expression data were normalized to gapdh, and human gene expression data were 
normalized to HPRT. Error bars represent variability (s.e.m.) across multiple independent experiments.  
 
Library preparation, RNA sequencing and mapping of reads  
The SMARTSeq2 protocol41 was used to amplify mRNA with the addition of ERCC spike-in control 
(1µl of 1:1,000,000 dilution of mix 1 (4456740, Ambion) per sample). 
Nextera XT (Illumina) was used to generate multiplex sequencing libraries from amplified cDNA. 
Libraries were sequenced on a HiSeq 2500 running in rapid mode. The paired-end reads were then 
mapped to both the M. musculus genome (Ensembl v.38.77) as well as to ERCC sequences using the 
default settings on GSNAP (v.2014-10-07). Htseq-count42 (v.0.6.1p1 default options) was used to 
count the number of reads mapped to each gene. All the samples were analysed in a single experiment 
to avoid batch effects.  
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Sample quality assessment 
Three metrics were used to assess data quality: the fraction of reads that were mapped, the number of 
genes that had more than 10 reads per million (RPM) as well as the fraction of reads that were mapped 
to mitochondrial genes. Extended Data Fig. 1b-e displays these metrics, with each being shown as a 
function of the total read number per sample. A principal component analysis was run and outliers 
were defined as performing worse than average on all three of these metrics (Extended Data Fig. 1f). 
These analyses uncovered one clear outlier (sample name ‘‘E4.5_Sample1’’ – highlighted in grey), 
which was then excluded from all further downstream analyses. 
We also controlled for possible contamination with cells from the primitive endoderm. We verified that 
the E5.0 samples do not show any expression of primitive endoderm markers like Gata6, Gata4, 
Sox17, Sox7 and Pdgfra. As for samples from E4.5 and E4.75 embryos, they all cluster with the 
epiblast samples previously published by Boroviak et al (see Extended Data Fig. 1g), except for one 
sample (“E4.5_Sample3”) that was found in the primitive endoderm cluster and was therefore excluded 
from further analysis (see below for details on the clustering algorithm).  
The samples that passed the quality check were normalized for sequencing depth using size factors43 
calculated on endogenous genes.  	
Principal component analysis and hierarchical clustering 
The principal component analyses (PCAs) plots shown in Fig. 1b and Extended Data Fig. 1f and h 
were generated using the log10-transformed read counts (by summing 1 to avoid infinities) of the 
union of the 5,000 most highly expressed genes in each sample.  
The hierarchical clustering shown in Fig. 1c and Extended Data Fig. 1g was based on the dissimilarity 
matrix defined as (1-ρ)/2, where ρ is the Spearman correlation coefficient between pairs of samples or 
genes. Once the dissimilarity matrix was calculated, the hierarchical tree was generated with the R 
function “hclust” with the “average” agglomeration method.  
 
Differential Expression Analysis  
The Bioconductor package DESeq244 was used to find differentially expressed genes between E5.0 
samples and E4.5-E4.75 samples at a 0.1 false discovery rate. Before running DESeq2, genes with an 
average expression level of less than 1 normalized read counts across all samples were excluded. 
 
Comparing our dataset to data in Boroviak et al 
In Extended Data Fig. 1h, before selecting the genes for the PCA, we pooled together our data with the 
ICM and epiblast samples previously published in Boroviak et al (FPKM normalized read-counts 
available from the cited paper) and performed a quantile normalization.  
The log-fold-changes plotted in Extended Data Fig. 1i were computed after adding a pseudo-count of 
0.1. The genes used for the clustering in Supplementary Extended Data Fig. 1g are those differentially 
expressed between epiblast and primitive endoderm at E4.5 as reported by Boroviak et al. 
 
Statistical analyses: Statistical analyses were performed using GraphPad Prism (excluding the 
analysis of the sequencing data). Embryos were randomly allocated to control and experimental 
groups. Sample size was determined based on previous experimental experience. Investigators were not 
blinded to group allocation. Quantitative data is presented as a contingency table and was analyzed 
with a Chi-square test. Quantitative data is presented as mean ± s.e.m. and was analyzed for normality 
using a D’Agostino-Pearson omnibus normality test. Data that presented a Gaussian distribution was 
analyzed using a two-tailed unpaired Student’s test (two groups) or an ANOVA test (multiple groups) 
with a Tukey’s multiple comparison test. Significant differences in the variance were taken into 
account using a Welch’s correction. Data that did not present a Gaussian distribution was analyzed 
using a Mann-Whitney test (two groups) or a Kruskal-Wallis test (multiple groups) with a Dunn’s 
multiple comparison test. For all quantifications a minimum of two independent experiments was 
performed. Sequencing data was analyzed with standard programs and packages. Code is available on 
request. 
 
Data availability statement: RNA sequencing data is available at Array Express under accession 
number E-MTAB-5147. The immunofluorescence and time-lapse data that support the findings of this 
study are available from the corresponding author upon reasonable request. Source data for RT-PCR 
experiments and quantifications of the immunofluorescence data are provided with the paper.  
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Extended Data Figure Legends 
 
Extended Data Figure 1: Epiblast gene expression patterns at peri-implantation stages. a, CAG-
GFP positive embryos recovered at peri-implantation stages, before and after dissection of the epiblast. 
(n=4 E4.5, 4 E4.75 and 4 E5.0 embryos) b-f, For all the collected samples we computed the total 
number of read counts (b), the fraction of reads mapped to endogenous genes (c), the number of genes 
with more than 10 reads per million (d) and the fraction of reads mapped to mitochondrial genes (e). A 
PCA of these metrics is shown in f. The sample coloured in grey (E4.5_Sample1) is characterised by a 
very low fraction of mapped reads and number of genes detected and was therefore removed from all 
downstream analysis. g, Hierarchical clustering of the E4.5-E4.75 samples that passed the quality 
check (black) and samples from the epiblast (red) and primitive endoderm (blue) at E4.5 from 
Boroviak et al. Only one sample (E4.5_Sample3, grey) clusters with the primitive endoderm, while all 
the others cluster together with epiblast. This sample was excluded from further analysis. h, PCA of 
our samples and samples from Boroviak et al. i, Log-fold-change of pluripotency marker genes 
between E5.0 and E4.5-E4.75 samples in our dataset (x-axis) and log-fold-change between E5.5 and 
E4.5 epiblast samples from Boroviak et al (y-axis). Squares, circles and triangles mark genes 
differentially expressed in both datasets, only in our dataset or only in Boroviak et al dataset 
respectively. The naïve pluripotency genes significantly downregulated at E5.5 were highly enriched 
among genes downregulated at E5.0 (p-value 7x10-8, Fisher’s exact test), whereas the enrichment of 
upregulated early post-implantation factors was only marginally significant (p-value=0.03, Fisher’s 
exact test).  j, Brightfield images of cells derived from embryos cultured in IVC1 (0/6 mESC colonies 
from IVC1 embryos and 4/6 mESC colonies from IVC1 +2i/LIF embryos). Scale bars, 50 µm. k, 
Immunostaining of mESCs derived from embryos cultured in IVC1 +2i/LIF for 24 hours. Scale bars, 
10 µm. l, Experimental set-up. A: analysis. m, Immunostaining of mouse embryos cultured as indicated 
in panel l. Dotted lines denote the epiblast and the arrow points to the pro-amniotic cavity. Scale bars, 
20 µm. n, Lumen formation in embryos rom panel k (n=12 IVC1 control  and 15 IVC1 experimental 
embryos). Chi-square test, *p=0.0137.  
 
Extended Data Figure 2: Dynamics of polarization, lumenogenesis and naïve pluripotency exit in 
mESCs. a, Experimental set-up. A: analysis. b-c, Immunostaining of mESCs in 3D matrigel. Red long 
arrows indicate the position used to plot intensity profiles (below). Yellow arrows indicate polarization 
and white arrows lumen formation. Scale bars, 10 µm. d, Quantification of lumen formation in cells 
from panels b  and c (n=21 (2 cells), 22 (4 cells) , 20 (8 cells) and 21 (>10 cells) spheroids per group). 
Chi-square test, ***p<0.0001. e, Fluorescence intensity in cells from panel f. Raw fluorescence 
intensity values were normalized to the fluorescence intensity of reporter cells cultured in gelatin 
2i/LIF throughout the movie (n=55 Nanog-YFP, 92 ΔPE-Oct4-GFP and 63 Rex1::GFPd2 spheroids). f, 
Time-lapse frames of naïve reporter mESCs cultured in matrigel without 2i/LIF. mT: membrane 
tomato. Time is indicated as hours:minutes. Dotted lines indicate the ouline of the spheroids at the end 
of the experiment. Scale bars, 20 µm. g-o, Expression of pluripotency genes in mESCs cultured in 
gelatin or matrigel, with or without 2i/LIF (n=5 (24 h), 3 (36 h), 3 (48 h) independent samples for 
Nanog, Esrrb, and Otx2; n=5 (24 h), 3 (36 h), 4 (48 h) independent samples for Fgf5; n=4 (24 h), 3 (36 
h), 3 (48 h) independent samples for Klf4, and Klf2; n=4 (24 h), 3 (36 h), 4 (48 h) independent samples 
for Zfp42; and n=3 (24 h), 3 (36 h), 3 (48 h) independent samples for Tbx3 and Pou5f1). Unpaired 
Student’s t test, ns: non-significant, nd: non-detected.  p, Immunostaining of mESCs cultured in 3D 
matrigel. Scale bars, 10 µm. All panels: gelatin (G), matrigel (M). 
 
Extended Data Figure 3: mESCs initiate polarisation in naïve conditions in a 3D matrigel 
culture. a, Experimental set-up. A: analysis. b, Immunostaining of mESCs cultured as indicated in 
panel a. Arrows point to lumens. Scale bars, 5 µm. c, Lumen formation in cells from panel b (n=31 (2 
cells, G +2i/LIF), 30 (4 cells, G +2i/LIF), 31 (2 cells, G -2i/LIF) and 31 (4 cells, G -2i/LIF) spheroids 
per condition). Chi-square test, ***p<0.0001. d, Internuclear distance in cells from Figure 2b (n=31 
(+2i/LIF) and 30 (-2i/LIF) spheroids per condition). Mann Whitney U test, ns: non-significant. e-g, 
Immunostaining of mESCs cultured in matrigel with or without 2i/LIF. Squares denote magnified 
regions. Scale bars, 10 µm (panels e and f) and 5 µm (panel g). h-j, Representative frames from time-
lapse experiments using different naïve reporter mESC lines, cultured in either gelatin or matrigel in 
the presence of 2i/LIF. Time is indicated as hours:minutes.  Scale bars, 50 µm. k-m, Intensity of 
Nanog-YFP, ΔPE-Oct4-GFP and Rex1::GFPd2 mESCs analyzed by time-lapse microscopy (panels h-j) 
(n=65 Nanog-YFP, 55 ΔPE-Oct4-GFP and 43 Rex1::GFPd2 mESC colonies -gelatin-; and n=61 
Nanog-YFP, 84 ΔPE-Oct4-GFP and 61 Rex1::GFPd2 mESC spheroids -matrigel-).  n, Experimental 
set-up. o, Immunostaining of mESCs cultured as indicated in panel n. Squares denote magnified 
	 23	
regions. Dotted lines demarcate the border of the colonies. The nucleus-centrosome angle (α) measured 
in p is indicated. Scale bars, 10 µm. p, Histogram of the angle between the centrosome-nucleus axis 
and the basal-apical axis of cells in the border of the colonies (panel o). Data is shown as relative 
frequencies (%) (n=76 (M +2i/LIF cultured in gelatin), 61 (M -2i/LIF cultured in gelatin), 62 (M 
+2i/LIF) and 60 (M -2i/LIF) centrosomes per condition). Kruskal-Wallis test, ***p<0.0001, ns: non-
significant. q, Immunostaining of control and Dgcr8 KO mESCs (with or without 2i/LIF). Scale bars, 5 
µm. r, Angle between the nucleus-centrosome axis and the nuclear-nuclear axis in cells from panel q. 
Each dot represents an individual centrosome (n=60 control +2i/LIF, 62 control -2i/LIF, 56 Dgcr8 KO 
_2i/LIF and 58 Dgcr8 KO -2i/LIF centrosomes per condition). Kruskal-Wallis test, ns: non-significant. 
s, Internuclear distance in cells from panel q (n=30 control +2i/LIF, 31 control -2i/LIF, 28 Dgcr8 KO 
+2i/LIF and 29 Dgcr8 KO -2i/LIF spheroids per condition). Kruskal-Wallis test, ns: non-significant. t, 
Nanog intensity in cells from panel q (n=30 control +2i/LIF, 31 control -2i/LIF, 28 Dgcr8 KO +2i/LIF 
and 30 Dgcr8 KO -2i/LIF spheroids per condition). Kruskal-Wallis test, ***p<0.0001, ns: non-
significant. u, Immunostaining of mESCs cultured in matrigel with or without Gö6983. Scale bars, 10 
µm. v, Internuclear distance in cells from Figure 2i (n=26 (+Gö6983) and 28 (-Gö6983) spheroids per 
condition). Mann Whitney U test, ns: non-significant.  All panels: matrigel (M). 
 
Extended Data Figure 4: 2i/LIF inhibits lumen formation in mESCs. a, Immunostaining of mESCs 
cultured in matrigel. Scale bars, 10 µm. b,  Immunostaining of Rex1::GFPd2 mESCs cultured in 
matrigel. Scale bars, 10 µm. c, Oct4, Nanog and Rex1::GFPd2 fluorescence intensity in cells from 
panels a and b (n=30 spheroids per condition (Nanog); n=21 (+2i/LIF) and 20 (-2i/LIF) spheroids 
(Oct4); and 21 (+2i/LIF) and 20 (-2i/LIF) spheroids (Rex1::GFPd2)). Unpaired Student’s t test, 
***p<0.0001, ns: non-significant. d-e, Electron microscopy images of mESCs cultured in matrigel 
with or without 2i/LIF. Arrowheads point to lumens. a: Golgi apparatus, b: basal cell-cell adhesion 
sites, c: Tight Junctions. Scale bars, 2 µm (panel d) and 500 nm (panel e). f-g, Immunostaining of 
mESCs cultured in matrigel. Squares denote magnified regions. Arrows point to inner non-polarized 
cells. Scale bars, 10 µm. h, Polarization in cells from panel g and Figure 3c (n=27 (+2i/LIF 48 h), 26 (-
2i/LIF 48 h), 24 (+2i/LIF 72 h) and 24 (-2i/LIF 72 h) spheroids per condition). Chi-square test, 
***p<0.0001. i, Experimental set-up. A: analysis j, Immunostaining of mESCs cultured as indicated in 
panel i. Arrows point to lumens. Scale bars, 10 µm. k, Lumen formation in cells from panel j (n=20 
spheroids per condition). Chi-square test, ns: non-significant. l, Nanog intensity in cells from panel j 
(n=20 spheroids per condition). ANOVA test, ***p<0.0001. m, Immunostaining of mESCs cultured in 
matrigel with different combinations of inhibitors. Arrows point to lumens. Scale bars, 10 µm. n, 
Lumen formation in cells from panel m (n=20 spheroids per condition). Chi-square test, ***p<0.0001. 
o, Nanog intensity in cells from panel m (n=20 spheroids per condition). ANOVA test, ***p<0.0001, 
ns: non-significant. p, Immunostaining of mESCs cultured in matrigel with a single 
inhibitor/supplement. Arrows point to lumens. Scale bars, 10 µm. q,  Nanog intensity in cells from 
panel p as a function of their ability to undergo lumenogenesis (n=30 (+2i/LIF control), n=50 (+LIF), 
n=48 (+GSK3i), n=51 (+MEKi) and n=39 (-2i/LIF) spheroids per condition). Mann Whitney U test, 
**p=0.0055, ***p<0.0001, ns: non-significant. All panels: matrigel (M).  
 
Extended Data Figure 5: Exit from naïve pluripotency is required for lumenogenesis in mESCs. 
a,. Immunostaining of control and Dgcr8 KO mESCs (with or without 2i/LIF). Scale bars, 10 µm. b, 
Lumen formation in cells from panel a (n=20 (control +2i/LIF), 20 (control -2i/LIF), 20 (Dgcr8 KO 
+2i/LIF) and 27 (Dgcr8 KO -2i/LIF) spheroids per condition). Chi-square test, *p=0.024. c, Nanog 
intensity in cells from a (n=20 (control +2i/LIF), 20 (control -2i/LIF), 20 (Dgcr8 KO +2i/LIF) and 27 
(Dgcr8 KO -2i/LIF) spheroids per condition). ANOVA test, ***p<0.0001. d, Nanog intensity in Dgcr8 
KO mESCs after 72 hours of 3D matrigel culture (panel a), as function of their ability to undergo 
lumenogenesis (n=6 (lumen) and 21 (no lumen) spheroids per condition). Unpaired Student’s t test, 
*p=0.0208. e, Immunostaining of mESCs cultured in matrigel with or without Gö6983. Scale bars, 10 
µm. f, Lumen formation in cells from panel e (n=30 spheroids per condition). Chi-square test, 
***p<0.0001. g, Immunostaining of Rex1::GFPd2 mESCs cultured in matrigel with or without 
Gö6983. Scale bars, 10 µm. h, Nanog, Rex1::GFPd2 and Oct4 intensity in cells from panels e and g 
(n=30 spheroids per condition (Nanog); 41 (+Gö6983) and 40 (-Gö6983) spheroids (Oct4 and 
Rex1::GFPd2)). Mann Whitney U test, **p=0.0002, ***p<0.0001. i, Experimental set-up. A: analysis. 
j, Immunostaining of mESCs cultured as indicated in panel i. The percentage of structures showing the 
representative phenotype is indicated. Scale bars, 5 µm.  k, Nanog intensity in cells from panel j as a 
function of their ability to undergo lumenogenesis (n=13 (no lumen) and 20 (lumen) spheroids per 
condition). Unpaired Student’s t test, ***p<0.0001. l, Immunostaining of mESCs cultured as indicated 
in panel i. The percentage of structures showing the representative phenotype is indicated. Scale bars, 
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10 µm. m, Nanog intensity in cells from panel l as a function of their ability to undergo lumenogenesis 
(n=14 (no lumen) and 17 (lumen) spheroids per condition). Unpaired Student’s t test, ***p<0.0001. n, 
Immunostaining of DOX-inducible Nanog mESCs. Scale bars, 10 µm. o, Lumen formation in cells 
from panel n (n=30 (+2i/LIF/DOX), 30 (+2i/LIF), 31 (+DOX) and 28 (-2i/LIF) spheroids per 
condition). Chi-square test, ns: non-significant. p, Nanog intensity in cells from n (n=30 
(+2i/LIF/DOX), 30 (+2i/LIF), 31 (+DOX) and 28 (-2i/LIF) spheroids per condition). Kruskal-Wallis 
test, ***p<0.0001. q, mRNA levels of Nanog and Otx2 in DOX-inducible Nanog mESCs (n=5 
(Nanog) and 3 (Otx2) independent samples per group. Unpaired Student’s t test, **p=0.0044, ns: non-
significant. r, mRNA levels of naïve pluripotency genes in DOX-inducible Nanog mESCs (n=4 
independent samples per group). Unpaired Student’s t test, **p=0.0075, ns: non-significant. s, 
Immunostaining of control and Nanog knock-down mESCs. Scale bars, 10 µm. t, Lumen formation in 
cells from panel s (n=20 (control siRNA) and 42 (Nanog siRNA) spheroids per condition). Chi-square 
test, ns: non-significant. u, Nanog and Rex1::GFPd2 intensity in cells from panel s (n=20 (control 
siRNA) and 42 (Nanog siRNA) spheroids per condition). v, Correlation between Nanog and 
Rex1::GFPd2 levels in cells from panel s. (n=20 (control siRNA) and 42 (Nanog siRNA) spheroids per 
condition). w, Otx2 and Oct4 fluorescence intensity in Oct4 knock-down mESCs (n=19 (lumen) and 28 
(no lumen) spheroids per condition). x, Immunostaining of control and Oct4 knock-down mESCs. 
Scale bars, 10 µm. All panels: arrows point to lumens; matrigel (M).  
 
Extended Data Figure 6: Sialomucins are required for mESC lumenogenesis. a, mRNA levels of 
Podxl in mESCs (n=5 (24 h), 3 (36 h) and 4 (48 h) independent samples per time point). Unpaired 
Student’s t test *p=0.0395 (gelatin 24 h), *p=0.0481 (matrigel 24 h), **p=0.0038 (gelatin 36 h), 
*p=0.0126 (matrigel 36 h), **p=0.0075 (gelatin 48 h), *p=0.0139 (matrigel 48 h). b, Immunostaining 
of mESCs cultured in 3D matrigel. Arrows indicate lumens. Scale bars, 10 µm. c, Immunostaining of 
control and Dgcr8 KO mESCs cultured in matrigel with or without 2i/LIF. Arrows indicate lumens. 
Scale bars, 10 µm. d, Immunostaining of mESCs cultured in matrigel with or without Gö6983. Arrows 
indicate lumens. Scale bars, 10 µm. e, Immunostaining of control and Podxl knock-down mESCs. A 
binarized image of the Podxl channel was used to determine presence or absence of Podxl. The 
percentages indicate the proportion of spheroids with (w/) or without (w/o) Podxl in the Podxl siRNA 
group. Arrows indicate lumens. Scale bars, 10 µm. f, Lumen formation in cells from panel e (n=43 
(control), 45 (Podxl siRNA w/Podxl) and 35 (Podxl siRNA w/o Podxl) spheroids per condition). Chi-
square test, ***p<0.0001. g, mRNA levels of early post-implantation factors in control and Podxl 
knock-down mESCs 24 hours after removal of 2i/LIF (n=3 independent samples per group). Student’s t 
test, ns: non-significant. h, mRNA levels of naïve pluripotency genes in control and Podxl knock-down 
mESCs 24 hours after removal of 2i/LIF (n=3 independent samples per group). Student’s t test, ns: 
non-significant. i, Immunostaining of control and Podxl knock-down mESCs cultured in matrigel. 
Arrows indicate polarization. Scale bars, 5 µm. j, Centrosome positions in cells from panel i. Each dot 
represents an individual centrosome (n=40 (control siRNA) and 36 (Podxl siRNA) centrosomes per 
condition). Mann Whitney U test, ns: non-significant. k, Internuclear distance in cells from panel i 
(n=20 (control siRNA) and 18 (Podxl siRNA) spheroids per condition). Unpaired Student’s t test, ns: 
non-significant. l, Immunostaining of Podxl heterozygous (HET) and KO mESCs. One KO clone is 
shown as an example. Arrows indicate lumens. Scale bars, 10 µm. m, Lumen formation in cells from 
panel l (n=30 (HET), 33 (clone 1) and 20 (clone 2) spheroids per condition) Chi-square test, ns: non-
significant. n, Immunostaining of control and Podxl knock-down mESCs with or without GFP-Cd34 
overexpression. Arrows point to lumens. Scale bars, 10 µm.  o, Lumen formation in cells from panel n 
(n=37 (control siRNA), 29 (Podxl siRNA), 33 (control siRNA +GFP-Cd34) and 31 (Podxl siRNA 
+GFP-Cd34) spheroids per condition). Chi-square test, ***p<0.0001, ns: non-significant. p, mRNA 
levels of sialomucin proteins in control and Podxl knock-down mESCs (with or without GFP-Cd34 
overexpression) 48 hours after removal of 2i/LIF (n=4 (without GFP-Podxl) and 6 (with GFP-Podxl) 
independent samples). Unpaired Student’s t test, *p=0.0145, ***p=0.0001, ns: non-significant. All 
panels: matrigel (M), gelatin (G).. 
 
Extended Data Figure 7: Otx2 and Oct4 induce Podxl expression upon naïve pluripotency exit. a, 
mRNA levels of Fgf5 and Podxl in wild-type (WT) and Otx2 KO mESCs at different time points after 
removal of 2i/LIF (n=2 independent samples per group). ANOVA test, **p=0.0092, ***p<0.0001. b-c, 
Immunostaining of WT and Otx2 KO mESCs cultured in matrigel. d, Lumen formation in cells from 
panel b and c (n=46 (WT 48 h), 34 (WT 72 h), 36 (Otx2 KO 48 h) and 35 (Otx2 KO 72 h) spheroids 
per condition). Chi-square test, ***p<0.0001. e, Immunostaining of Otx2 KO mESCs with or without 
overexpression of Otx2 (addition of DOX). f, Lumen formation in cells from panel e and in WT 
mESCs cultured without 2i/LIF and with/without Otx2 overexpression (n=19 (WT), 20 (WT Otx2), 20 
	 25	
(WT Otx2 DOX), 20 (Otx2 KO), 20 (Otx2 KO Otx2) and 23 (Otx2 KO Otx2 DOX) spheroids per 
condition). Chi-square test, ***p<0.0001. g, Immunostaining of Otx2 KO mESCs with or without 
overexpression of Otx2 (addition of DOX). h, Lumen formation in cells from panel g and in Otx2 KO 
mESCs cultured with 2i/LIF and with/without Otx2 overexpression (n=20 (WT), 20 (WT Otx2), 50 
(WT Otx2 DOX), 19 (Otx2 KO), 21 (Otx2 KO Otx2) and 20 (Otx2 KO Otx2 DOX) spheroids per 
condition). Chi-square test, *p=0.0196, ***p<0.0001. i-j, Nanog (i) and Otx2 (j) intensity in cells from 
panel g as a function of their ability to undergo lumogenesis (n=25 spheroids per condition) Mann 
Whitney U test, ***p<0.0001. k, mRNA levels of naïve pluripotency genes in WT and Otx2 KO 
mESCs at different time points after removal of 2i/LIF (n=2 independent samples per group). ANOVA 
test, *p=0.02, **p=0.0045, ***p=0.0002 (Klf4), ***p=0.0001 (Tbx3). l, Immunostaining of WT and 
Otx2 KO mESCs overexpressing GFP-Podxl. m, Lumen formation in cells from panel l (n=66 (WT) 
and 61 (Otx2 KO) spheroids per condition). Chi-square test, ns: non-significant. n, ChIP-Seq analysis 
of Oct4, Otx2 and H3K27ac in ESC (top) and after 48 hours of transition into Epiblast like cells 
(EpiLCs, bottom). Shaded area indicates an enhancer within the first intron of Podxl that is activated 
during cell fate transition. q, Immunostaining of GFP-Podxl overexpressing mESCs. Arrows indicate 
lumens. Scale bars, 10 µm. r, Lumen formation in cells from panel q (n=30 (+2i/LIF clone 1), 32 (-
2i/LIF clone 1), 33 (+2i/LIF clone 2) and 34 (-2i/LIF clone 2) spheroids per condition) Chi-square test, 
***p<0.0001. All panels: arrows indicate lumens; matrigel (M); scale bars, 10 µm. 
 
Extended Data Figure 8: Cgn is induced upon naïve pluripotency exit and mediates Rab11 vesicle 
tethering to the apical membrane: a, mRNA levels of Cgn in mESCs (n=5 (24 h), 3 (36 h) and 4 (48 
h) independent samples per group). Unpaired Student’s t test, *p=0.0431 (gelatin 24 h), *p=0.0347 
(matrigel 24 h), ***p=0.0003 (gelatin 36 h), *p=0.0126 (matrigel 36 h), **p=0.0075 (gelatin 48 h), 
*p=0.0139 (matrigel 48 h). b-c, Immunostaining of mESCs cultured in matrigel with or without 2i/LIF. 
Squares denote magnified regions. d, mRNA levels of naïve pluripotency genes and early post-
implantation factors in control and Cgn knock-down mESCs (n=3 independent samples per group). 
Unpaired Student’s t test, ***p<0.0001, ns: non-significant. e, Immunostaining of Rex1::GFPd2 
mESCs in control and Cgn knock-down mESCs. All panels: matrigel (M); scale bars, 10 µm. 
 
Extended Data Figure 9: Characterization of pluripotency gene expression and epiblast 
morphogenesis in post-implantation human embryos. a, Immunostaining of day 9-10 human 
embryos. Dotted lines indicate the epiblast and arrows the amniotic cavity. Scale bars, 50 µm and 10 
µm (magnified areas). b, Nanog intensity in embryos from panel a (n=6 embryos per condition). Mann 
Whitney U test, *p=0.0381. c, 3D reconstruction of the epiblast (based on the KLF17 staining) and the 
amniotic cavity (based on the PODXL staining) of embryos from Figure 6b. d, Immunostaining of day 
9-10 human embryos. (n=2 embryos per group). Scale bars, 50 µm. e, Immunostaining of day 9-10 
human embryos. Scale bars, 50 µm. f, Number of apoptotic cells per embryo in embryos from panel d 
(n=3 and 5 embryos per condition). Mann Whitney U test, *p=0.0179. 
 
Extended Data Figure 10: Exit from naïve pluripotency is required for lumenogenesis in hESCs. 
a, Immunostaining of WIBR3 ΔPE-OCT4-GFP cultured in primed FBS/KSR/bFGF2 medium or 
N2B27 2i/hLIF with or without DOX. DOX addition induces the expression of NANOG and KLF2. 
Scale bars, 20 µm. b-c, mRNA levels of pluripotency genes in cells from panel a (n=3 independent 
samples per condition). ANOVA test, ***p<0.0001 (NANOG and KLF2), ***p=0.0001 (TFCP2L1), 
**p=0.0013 (DNMT3L). d, Immunostaining of WIBR3 ΔPE-OCT4-GFP cultured in matrigel in primed 
or naïve conditions. Arrows indicate lumens. Scale bars, 20 µm. e, Lumen formation in cells from 
panel d (n=38 (2iL/DOX), 33 (2iL -DOX), 34 (FBS/KSR/bFGF2) and 20 (mTESR) spheroids per 
condition). Chi-square test, ***p<0.0001. f-h, mRNA levels of pluripotency genes and early post-
implantation factors in cells from panel i (n=4 (NANOG, KLF2, TFCP2L1, DNMT3L, KLF4 and 
PODXL) and 3 (KLF17) independent samples per group). Kruskal Wallis test, ***p=0.0002 (NANOG), 
***p<0.0001 (KLF2, DNMT3L, KLF4, PODXL), **p=0.0058 (TFCP2L1), *p=0.0205 (KLF17). i, 
Immunostaining of WIBR3 ΔPE-OCT4-GFP cultured in primed mTESR medium or naïve conditions 
(2iL/DOX, 5iLAF and RSet). Scale bars, 10 µm. j, Immunostaining of hESCs cultured in 3D matrigel 
under different naïve and primed conditions. Arrows indicate lumens. Scale bars, 10 µm. k, Lumen 
formation in cells from panel j (n=31 (2iL/DOX), 27 (5i/LAF), 33 (RSet) and 20 (mTESR) spheroids 
per condition). Chi-square test, **p=0.0019, ***p<0.0001. l, Immunostaining of hESCs cultured in 3D 
matrigel under different naïve and primed conditions. Arrows point to polarized centrosomes. Scale 
bars, 5 µm. m, Angle between the nucleus-centrosome axis and the nuclear-nuclear axis in cells from 
panel l. Each dot represents an individual centrosome (n=53 (2iL/DOX), 51 (5i/LAF), 40 (RSet) and 42 
(mTESR) centrosomes per condition). Kruskal Wallis test, ns: non-significant. n, Immunostaining of 
	 26	
naïve hESCs cultured in 3D matrigel with mTESR. The initial naïve conditions in which the cells were 
cultured are indicated. Arrows indicate lumens. Scale bars, 10 µm. o, Lumen formation in cells from 
panel n (n=30 (2iL/DOX 48 h), 30 (2iL/DOX 72 h), 30 (5i/LAF 48 h), 29 (5i/LAF 72 h) 30 (RSet 48 h) 
and 30 (RSet 72 h) spheroids per condition and time point). All panels: matrigel (M). 
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Supplemental Table and Video Legends 
 
 
Supplementary Table 1: Genes expressed in the mouse epiblast at peri-implantation stages.  
 
Supplementary Table 2: Antibodies used in this study. 
 
Supplementary Table 3: List of RT-PCR primers used in this study. 
 
Supplementary Video 1: ΔPE-Oct4-GFP mESCs cultured in 3D matrigel without 2i/LIF and imaged 
every 30 minutes. The arrow points to the cell shown in Extended Data Fig. 2e. The maximum 
projection is shown throughout the movie. Scale bars, 50 µm. 
 
Supplementary Video 2: Rex1::GFPd2 mESCs cultured in 3D matrigel without 2i/LIF and imaged 
every 30 minutes. The arrow points to the cell shown in Extended Data Fig. 2e. The maximum 
projection is shown throughout the movie. Scale bars, 50 µm. 
 
Supplementary Video 3: Nanog-YFP mTmG mESCs cultured in 3D matrigel without 2i/LIF and 
imaged every 30 minutes. The arrow points to the cell shown in Extended Data Fig. 2e. The maximum 
projection is shown throughout the movie. Scale bars, 50 µm. 
 
 
 
